Efficacy of LCAR-T2C CAR-T cells

DRUG2 trials

Sponsors

The First Affiliated Hospital with Nanjing Medical University, Beijing Boren Hospital

Conditions

CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)T Cell LymphomaT-cell Leukemia

Phase 1

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma

TerminatedNCT04219319

The First Affiliated Hospital with Nanjing Medical UniversityCD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

Start: 2021-12-15End: 2022-07-20Updated: 2022-08-16

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

TerminatedNCT04973527

Beijing Boren HospitalT-cell Leukemia, T Cell Lymphoma

Start: 2021-07-02End: 2022-07-20Updated: 2022-08-16